Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma.
Liu Z, Cheng X, Pang B, Wang S, Liu B, Cao C, Qian R, Liang W, Zhu Y, Li P, et al. Int Immunopharmacol. 2022 Mar; 104:108399. Epub 2022 Jan 8.